Синдром поликистозных яичников - предиктор повышенного риска сердечно-сосудистых заболеваний у женщин в климактерии? (Обзор литературы)
Аннотация
К настоящему времени главной причиной смертности в мире среди женщин являются сердечно-сосудистые заболевания. Синдром поликистозных яичников (СПЯ) связывают с неблагоприятным кардиометаболическим профилем с раннего возраста. Считается, что наравне с дислипидемией, ожирением и манифестацией сахарного диабета второго типа андрогены влияют на состояние сердечно-сосудистой системы. Возникает вопрос: действительно ли женщины с СПЯ больше подвержены риску сердечно-сосудистых заболеваний в более позднем возрасте? В настоящем обзоре мы попытались сосредоточиться на этой предполагаемой связи на основании исследований различных этапов жизни женщин с СПЯ. Данные о сердечно-сосудистых заболеваниях и смертности в пери- и постменопаузе у женщин с СПЯ противоречивы. По-прежнему не ясно, оказывают ли андрогены протективное или, наоборот, неблагоприятное воздействие на проявления сердечно-сосудистых заболеваний. Для ответа на этот вопрос необходимо проведение больших проспективных фенотипированных когортных исследований женщин с СПЯ.
Об авторе
Я. З. Зайдиева
ГБУЗ МО «Московский областной научно-исследовательский институт акушерства и гинекологии»
Россия
Россия
Список литературы
1. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41-7.
2. March WA, Moore VM, Willson KJ, Phillips DII Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 2010; 25:544-51.
3. Williams DM, Palaniswamy S, Sebert S, et al. 25-Hydroxyvitamin D concentration and leukocyte telomere length in young adults: findings from the Northern Finland Birth Cohort 1966. Am J Epidemiol2016; 183: 191-8.
4. Legro RS, Spielman R, Urbanek M, Driscoll D, Strauss JF III, Dunaif A. Phenotype and genotype in polycystic ovary syndrome. Recent Prog Horm Res 1998; 53: 217-56.
5. Urbanek M, Legro RS, Driscoll DA, et al. Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin. Proc Natl Acad Sci USA 1999; 96: 8573-8.
6. Legro RS, Kunselman AR, Demers L, Wang SC, Bentley-Lewis R, Dunaif A. Elevated dehydroepiandrosterone sulfate levels as the reproductive phenotype in the brothers of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2002; 87: 2134-8.
7. Wild RA, Carmina E, Diamanti-Kandarakis E, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab 2010; 95:2038-49.
8. Fauser BC, Tarlatzis BC, Rebar RW, et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril2012; 97:28-38 e25.
9. Legro RS, Arslanian SA, Ehrmann DA, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2013; 98: 4565-29.
10. Goverde AJ, van Koert AJ, Eijkemans MJ, et al. Indicators for metabolic disturbances in anovulatory women with polycystic ovary syndrome diagnosed according to the Rotterdam consensus criteria. Hum Reprod 2009; 24: 710-17.
11. Broekmans FJ, Knauff EA, Valkenburg O, Laven JS, Eijkemans MJ, Fauser BC. PCOS according to the Rotterdam consensus criteria: change in prevalence among WHO-II anovulation and association with metabolic factors. Bjog 2006; 113: 1210-17.
12. Legro RS, Castracane VD, Kauffman RP. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstet Gynecol Surv 2004; 59: 141-54.
13. Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2010; 16: 347-63.
14. West S, Vahasarja M, Bloigu A, et al. The impact of self-reported oligo-amenorrhea and hirsutism on fertility and lifetime reproductive success: results from the Northern Finland Birth Cohort 1966. Hum Reprod 2014; 29: 628-33.
15. Boomsma CM, Eijkemans MJ, Hughes EG, Visser GH, Fauser BC, Macklon NS. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update2006; 12: 673-83.
16. Hart R, Norman R. Polycystic ovarian syndrome-prognosis and outcomes. Best Pract Res Clin Obstet Gynaecol 2006; 20: 751-78.
17. de Wilde MA, Veltman-Verhulbt SM, Goverde AJ, et al. Preconception predictors of gestational diabetes: a multicentre prospective cohort study on the predominant complication of pregnancy in polycystic ovary syndrome. Hum Reprod 2014; 29: 1327-36
18. Palomba S, de Wilde MA, Falbo A, Koster MP, La Sala GB, Fauser BC. Pregnancy complications in women with polycystic ovary syndrome. Hum Reprod Update 2015; 21: 575-92.
19. Recabarren SE, Smith R, Rios R, et al. Metabolic profile in sons of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2008; 93: 1820-6.
20. Sir-Petermann T, Codner E, Perez V, et al. Metabolic and reproductive features before and during puberty in daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2009; 94: 1923-30.
21. Mutlu B, Tigen K, Gurel E, Ozben B, Karaahmet T, Basaran Y. The predictive value of flow-mediated dilation and carotid artery intima-media thickness for occult coronary artery disease. Echocardiography 2011; 28: 1141-7.
22. Sprung VS, Atkinson G, Cuthbertson DJ, et al. Endothelial function measured using flow-mediated dilation in polycystic ovary syndrome: a meta-analysis of the observational studies. Clin Endocrinol (Oxf) 2013; 78: 438-46.
23. Kaya MG, Yildirim S, Calapkorur B, Akpek M, Unluhizarci K, Kelestimur F. Metformin improves endothelial function and carotid intima media thickness in patients with PCOS. Gynecol Endocrinol 2015; 31: 401-5.
24. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007; 115: 459-67.
25. Meyer ML, Malek AM, Wild RA, Korytkowski MT, Talbott EO. Carotid artery intima-media thickness in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2012; 18: 112-26.
26. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M, Jr., Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990; 15: 827-32.
27. Raggi P, Gongora MC, Gopal A, Callister TQ, Budoff M, Shaw LJ. Coronary artery calcium to predict all-cause mortality in elderly men and women. J Am Coll Cardiol 2008; 52: 17-23.
28. Detrano R, Guerci AD, Carr JJ, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med 2008; 358: 1336-45.
29. Talbott EO, Zborowski JV, Rager JR, Boudreaux MY, Edmundowicz DA, Guzick DS. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004; 89: 5454-61.
30. Talbott EO, Zborowski J, Rager J, Stragand JR. Is there an independent effect of polycystic ovary syndrome (PCOS) and menopause on the prevalence of subclinical atherosclerosis in middle aged women? Vasc Health Risk Manag 2008; 4: 453-62.
31. Shroff R, Kerchner A, Maifeld M, Van Beek EJ, Jagasia D, Dokras A. Young obese women with polycystic ovary syndrome have evidence of early coronary atherosclerosis. J Clin Endocrinol Metab 2007; 92: 4609-14.
32. Shaw LJ, Bugiardini R, Merz CN. Women and ischemic heart disease: evolving knowledge. J Am Coll Cardiol 2009; 54: 1561-75.
33. Regitz-Zagrosek V, Kararigas G. Mechanistic pathways of sex differences in cardiovascular disease. Physiol Rev 2017; 97: 1-37.
34. Sharaf BL, Pepine CJ, Kerensky RA, et al. Detailed angiographic analysis of women with suspected ischemic chest pain (pilot phase data from the NHLBI-sponsored Women’s Ischemia Syndrome Evaluation [WISE] Study Angiographic Core Laboratory). Am J Cardiol 2001; 87: 937-41; A3.
35. Anand SS, Islam S, Rosengren A, et al. Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. Eur Heart J 2008; 29: 932-40.
36. Elias-Smale SE, Gunal A, Maas AH. Gynecardiology: distinct patterns of ischemic heart disease in middle-aged women. Maturitas 2015; 81: 348-52.
37. Hart R, Doherty DA. The potential implications of a PCOS diagnosis on a woman’s long-term health using data linkage. J Clin Endocrinol Metab 2015; 100: 911-19.
38. Schmidt J, Landin-Wiihelmsen K, Brannstrom M, Dahlgren E. Cardiovascular disease and risk factors in PCOS women of postmenopausal age: a 21-year controlled follow-up study. J Clin Endocrinol Metab 2011;9 6: 3794-803.
39. Krentz AJ, von Muhlen D, Barrett-Connor E. Searching for polycystic ovary syndrome in postmenopausal women: evidence of a dose-effect association with prevalent cardiovascular disease. Menopause 2007; 14: 284-92.
40. Khatibi A, Agardh CD, Shakir YA, et al. Could androgens protect middle-aged women from cardiovascular events? A population-based study of Swedish women: the Women’s Health in the Lund Area (WHILA) Study. Climacteric 2007; 10: 386-92.
41. Elting MW, Korsen TJ, Bezemer PD, Schoemaker J. Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow-up study of a Dutch PCOS population. Hum Reprod 2001; 16: 556-60.
42. Zawadski JK, Dunaif A, Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In Dunaif JR, Givens F, Haseltine FP, Merriam GR, eds. Polycystic ovary syndrome. Boston (MA): Blackwell Scientific; 1992:377.
43. Azziz R, Carmina E, Dewailly D, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009; 91: 456-88.
44. Pierpoint T, McKeigue PM, Isaacs AJ, Wild SH, Jacobs HS. Mortality of women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol 1998; 51: 581-6.
45. Wild S, Pierpoint T, Jacobs H, McKeigue P. Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study. Hum Fertil (Camb) 2000; 3: 101-5.
46. Armeni E, Stamatelopoulos K, Rizos D, et al. Arterial stiffness is increased in asymptomatic nondiabetic postmenopausal women with a polycystic ovary syndrome phenotype. J Hypertens 2013; 31: 1998-2004.
47. Dahlgren E, Janson PO, Johansson S, Lapidus L, Oden A. Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand 1992; 71: 599-604.
48. Cibula D, Cifkova R, Fanta M, Poledne R, Zivny J, Skibova J. Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome. Hum Reprod 2000; 15: 785-9.
49. Merz CN, Shaw LJ, Azziz R, et al. Cardiovascular disease and 10-year mortality in postmenopausal women with clinical features of polycystic ovary syndrome. J Womens Health (Larchmt) 2016; 25: 875-81.
50. Polotsky AJ, Allshouse AA, Crawford SL, et al. Hyperandrogenic oligomenorrhea and metabolic risks across menopausal transition. J Clin Endocrinol Metab 2014; 99: 2120-7.
51. Shaw LJ, Bairey Merz CN, Azziz R, et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health-National Heart, Lung, and Blood Institute sponsored Women’s Ischemia Syndrome Evaluation. J Clin Endocrinol Metab 2008; 93: 1276.
52. Gunning M. N., Fauser B. C. J. M. Are women with polycystic ovary syndrome at increased cardiovascular disease risk later in life? Climacteric 2017; Vol. 20. Issue 3. P. 222-227.
Рецензия
Для цитирования:
Зайдиева Я.З. Синдром поликистозных яичников - предиктор повышенного риска сердечно-сосудистых заболеваний у женщин в климактерии? (Обзор литературы). Медицинский алфавит. 2017;4(37):37-43.
For citation:
Zaydieva Ya.Z. Polycystic ovary syndrome as high risk predictor of cardiovascular diseases in women in climacteric? (Literature review). Medical alphabet. 2017;4(37):37-43. (In Russ.)
Просмотров:
306
Послать статью по эл. почте 